89Bio Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Hello, and welcome to the sixth annual H.C. Wainwright NASH investor conference. My name is Ed Arce. I'm one of the senior biotech analysts here at H.C. Wainwright. And our next presenting company is 89bio, ticker ETNB. I'm very pleased to have with us the President and CEO, Rohan Palekar. Rohan, welcome.
Thanks, Ed. It's our pleasure to be at your next conference.
Excellent. Glad you're here. So I wanted to start, Rohan, with -- for those who ask or may not be familiar with the company. Just a brief overview, including the mechanism of your unique, potentially best-in-class FGF21, pegozafermin, and the rest of your pipeline.
Sure. So 89bio is a clinical-stage company focused on liver and cardio-metabolic disorders. Our lead program is pegozafermin, as Ed mentioned, which is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |